Five-hundred seventy-five white-collar workers (374 men; 99% Caucasians) aged 20-59 years were selected on the basis of their being healthy and clinically free from cardiovascular risk factors (except smoking and family history). We have observed a higher relative frequency of the e 3 allele in this population, as is true of populations with a low prevalence of coronary heart disease. Each of the 11 plasma lipid and lipoprotein traits studied was adjusted for age, weight, height, body mass index, plasma glucose, and uric acid in men and women separately. The influence of each of the three common apo E alleles on each adjusted trait was evaluated by use of the average excess statistic. We established that in a population selected for health, the c2 allele is associated with lower plasma levels of total cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B associated with LDL cholesterol in both men and women. Conversely, the e4 allele is associated with higher levels of these traits in women only. In contrast to the findings in populations not selected for health, the presence of the e2 allele in our subjects tended to be associated with lower and the e. 
Utermann et al 12 have shown that the phenotypic expression of the apo E alleles depends on the factors involved in determining hyperlipidemia. Previous studies of the influence of common apo E variants have used data collected by various sampling criteria. No study has been based on a sample specifically selected for health. With this consideration, we undertook a multifaceted study whose general purpose was to determine the lipid, lipoprotein, and apolipoprotein profiles of a reference population of individuals in good health and free from major clinically identifiable risk factors for atherosclerosis. We chose to study this sample to evaluate the influence of common variants of the apo E polymorphism, without the possible secondary effects of disease on lipid, lipoprotein, and apolipoprotein trait levels. This strategy provides an estimate of the relation between genotype variability and phenotype variability in healthy persons. Furthermore, because male gender is a major risk factor for coronary heart disease (CHD) and because women are uniquely exposed to factors known to influence lipid metabolism, we emphasize the comparisons between men and women in this study. This report focuses on 1) estimation of the common apo E allele frequencies; 2) determination of the influence of the apo E polymorphism on interindividual variability of traits that reflect lipid metabolism; 3) evaluation of gender differences in apo E allele effects on this variability; and 4) determination of the relative fraction of interindividual variability for each lipid, lipoprotein, and apolipoprotein trait attributable to variation in age, weight, height, body mass index (BMI), glucose, and uric acid (concomitant variables) and genotypic effects of the apo E polymorphism.
Methods

Sample Description
A sample of white-collar workers aged 20-59 years was selected from those employed by Hydro-Quebec, a major utility company in Montreal, Canada. This population was selected in view of the large number of workers available, its proximity to our research center, and the availability of medical records for all employees. Individuals were selected specifically for their health status to represent a population free from clinical manifestations of cardiovascular disease, hypertension, diabetes, chronic disorders requiring medication, previously diagnosed thyroid dysfunction, renal or liver dysfunction, or hyperlipidemia.
In an initial screening procedure the 3,028 available medical records were reviewed by trained clinical staff (nurses and physicians). Individuals were considered eligible if they had no clinical manifestations of metabolic disorders, no clinical or electrocardiographic manifestations of cardiovascular disease, and no hypertension, whether treated or untreated. Hypertension was defined as a blood pressure of 150/90 mm Hg or greater on any single occasion. Subjects were excluded if they had any one of the exclusion criteria listed in Table 1 . After this first screening, 2,008 individuals were identified as potential candidates for the study. A written invitation to participate was sent to 1,492 available individuals, of whom 788 (52.8%) expressed their willingness to participate, and 740 came for an interview.
Each participant was asked to complete a questionnaire concerning his/her past medical history and present condition, with emphasis on the cardiovascular system and on metabolic and chronic disorders. The use of prescription and nonprescription drugs was also queried. Completed questionnaires were reviewed by trained personnel who consulted with a physician (a full-time participant in this study) as needed. Subjects reporting positively for any of the exclusion criteria (Table 1) were immediately eliminated from consideration. In the absence of identifiable reasons for exclusion, subjects underwent a brief clinical examination, including determination of vital signs, height and weight measurement, and inspection for eye or skin signs of hyperlipidemia (xanthelasmas, xanthomas, etc.). At this time patients were again excluded on the basis of a blood pressure reading of 150/90 mm Hg or greater or a BMI of 30 or greater (BMI=weight in kilograms divided by height in meters squared).
A standardized interview was conducted by trained personnel with regard to smoking habits, physical activity, use of alcohol, dietary habits, and sources of perceived stress. Participants were asked to complete a form concerning the general medical history of their first-degree relatives and grandparents, with specific emphasis on cardiovascular events and causes of death. Information was also sought regarding ethnicity of the participants (68% were of French-Canadian extraction); this information was used later in a separate genetic study involving DNA polymorphisms. The completed form was returned at the time of blood sampling (1-2 weeks later). Of the 740 individuals who came for an interview, blood samples for plasma lipid, lipoprotein, and apolipoprotein levels as well as apo E phenotype and routine biochemistry analysis were obtained from 626 individuals (409 men and 217 women) between March 1986 and April 1987. The remaining 114 were excluded either on the basis of the study criteria (n = \00) or because of noncompliance regarding blood sampling (n = l4).
A posteriori exclusions included individuals with abnormal or missing baseline liver or kidney function tests, those with elevated blood glucose or uric acid levels, or those using medications that could potentially alter blood lipid levels. When first-degree relatives were present in the sample, all but the first individual examined were excluded from further study. These exclusions resulted in a sample of 588 (383 men and 205 women) unrelated individuals. One woman was eliminated from further analysis due to a missing glucose result. In addition, one man was found to have the rare e5 allele. 13 Because this research was focused on the influence of the common apo E alleles, this individual was removed from the study population, leaving 382 men and 204 women.
Laboratory Methods
After a 12-hour fast, blood samples for lipid, lipoprotein, and apolipoprotein determinations were obtained in tubes containing 1.5 mg/ml Na 2 EDTA and were centrifuged within 2 hours. Blood was also drawn for routine biochemistry analyses, including SMAC and liver function studies, that were analyzed in a separate accredited hospital facility. Plasma lipoproteins were separated under standard conditions by a combination of ultracentrifugation at d=1.006 g/ml to isolate VLDLs and heparin-manganese precipitation of the apo B-containing lipoproteins in the d= 1.006 g/ml infranatant to determine LDL and HDL concentrations according to the Lipid Research Clinics Protocol.
14 Thus, the LDL referred to in this article is material with a d> 1.006 g/ml. HDL2-C and HDL3-C levels were determined after precipitation of HDL2 with dextran sulfate. 15 Plasma and lipoprotein cholesterol 16 and TGs 17 were measured enzymatically on an automated analyzer (Abbott Bichromatic Analyzer model 100, Abbott Laboratories, Pasadena, Calif.).
Total and LDL apo B concentrations were measured by electroimmunoassay on total plasma and on the <i>1.006 g/ml ultracentrifugal fraction; the latter was taken to represent LDL apo B.
18 VLDL apo B was obtained by subtracting the LDL apo B from the total plasma value. In each assay a commercial serum (Behringwerke, Marburg, FRG) and a frozen serum pool were used as secondary standards. At the time of these measurements, the technique was not calibrated against the standard serum provided by the Centers for Disease Control, Atlanta, Ga., but the correction factor was found by division by 1.25.
The apo E phenotype was determined by the method of Bouthillier et al. 19 The apo E isoforms were separated by isoeleetric focusing, and the bands were stained with Coomassie blue and photographed. Each typing was checked by three independent blinded observers. In instances where discordant results were obtained (19/626 gels=3%), each observer reread the photographs. Obvious errors in interpretation were corrected. A consensus was obtained, with the exception of two gels where an E3/E3 phenotype was consistently read as an E3/E2 by one observer. These results were verified and confirmed as E3/E3 by focusing of the apo E bands in an immobilized pH gradient. 20 
Statistical Methods
All analyses employed the SAS software package developed by the SAS Institute. 21 Specialized techniques were programmed by use of an SAS interactive matrix language (PROC IML).
The means and standard deviations of all lipid, lipoprotein, and apolipoprotein traits were determined separately for men, women, and women not taking hormones. Individuals whose values were located beyond four standard deviations from the mean of their group for any one trait were eliminated from further analysis. It was assumed that each of these outliers represented a possible laboratory error, a nonfasting state, or unreported disease. We were left with subgroups of 374 men and 201 women; 143 women were not taking any form of hormonal preparation. We chose to study the latter group instead of those taking hormones because the former provided a larger and more homogeneous sample. Specifically, hormone users were taking one of a variety of oral contraceptive preparations or hormone replacement regimens.
To eliminate as much variability attributable to concomitant variables as possible, each lipid, lipoprotein, and apolipoprotein result was adjusted by linear regression for variation in age, age . Separate regression equations were estimated for men, women, and women not taking hormones. Subsequent evaluations of the influence of the apo E polymorphism were performed on the residuals from these regressions for each of the three groups.
Allele frequencies were estimated by the gene counting method. We employed the average excess statistic 2223 designated as a to evaluate the influence of each of the apo E alleles (aj, where i=2,3,4) on trait variability in each group: men, women, and women not taking hormones. The measure of average excess (as opposed to average effect) is appropriate to our study sample because all possible genotypes are not represented (absence of e2/e2 women in our sample). Because the theoretical sampling distribution of this statistic is unknown, we used permutation testing 24 to evaluate whether the difference between the influence of the less common e 2 and e 4 alleles and the influence of the most common e3 allele was statistically significant. Permutation testing involves randomly generating an empirical distribution of a statistical function of the sample. For each of the three subgroups, two functions of the data representing two null hypotheses were considered: a 2 -a 3 =0 and 04-0:3=0. Because the most common e3 allele has an expected mean near the population mean, a two-tailed test of these hypotheses was considered. The estimates of these contrasts, computed for the actual data, were initially compared with the distribution of estimates obtained from 1,000 random permutations of the sample. Each of the random samples was generated by randomly assigning the observed phenotypes to the observed genotypes (without replacement). The two contrasts of interest were computed for each permutation of the sample. The proportion of randomly generated contrasts that exceeded the original estimate computed on the observed sample of data was taken to be the probability that the original contrast was attributable to chance alone. When this probability was less than 0.05, we rejected the null hypothesis. This probability was estimated with error because 1,000 permutations of the sample are only a fraction of the total possible number of permutations of a sample of the size considered here. Whenever the estimate of probability of observing a contrast by chance was between 0.01 and 0.1, the distribution of the contrast was regenerated by use of 15,000 random samples to reduce the standard error of the estimate.
We next contrasted men with women by the use of subsets of individuals who carried the e 2, e3, or e 4 allele. The significance of the difference between men and women for the average phenotypic value of the three genotypes having at least one e 2 allele was tested by the repeated-sampling scheme presented above. This procedure was repeated to test gender differences separately for those carrying the e 3 and those carrying the e 4 allele. A significant difference between genders for a contrast based on data associated with one allele but not a second allele was interpreted as evidence for an allele by a gender interaction effect.
Last, the fraction of trait variability attributable to concomitant variables and genotypic effects was determined. The percentage of the total sum of squares attributable to concomitants and to genotypic variability was estimated by linear regression analysis. 25 
Results
The sample consisted of a majority of Caucasian (99%) individuals. The remaining 1% were of Asian descent and were unremarkable with respect to apo E phenotype or other measured traits.
The relative frequencies of the apo E alleles are shown in Table 2 . No significant differences between men and women were observed.
Twenty-nine percent of women in our sample («=58) were taking either oral contraceptives or postmenopausal hormonal replacement therapy. We chose to study the subgroup not taking any form of hormonal preparation (n = 143) to eliminate possible confounding effects. Again, there were no significant differences in relative allele frequencies between women not taking hormones and men ( Table 2 ). The relative genotype frequencies in all three samples were in Hardy-Weinberg equilibrium. Table 3 gives descriptive statistics for concomitant and dependent variables. All subjects had BMI, glucose, and uric acid levels within the laboratory normal range by virtue of the exclusion criteria. The means of lipid, lipoprotein, and apolipoprotein traits are also shown, with men having higher values for cholesterol, LDL-C, VLDL-C, TG, and LDL apo B than do women, while HDL-C is higher in women than in men. These observations are consistent with other reports from the literature. For all traits, women not taking hormones had mean values similar to those of women taking hormones.
Appendix 1 presents the average adjusted lipid, lipoprotein, and apolipoprotein levels for each of the apo E genotypes in men, women, and women not taking hormones.
The estimates of average excess for each of the three common apo E alleles for each of the lipid, lipoprotein, and apolipoprotein traits (adjusted for variation in concomitants) is given in Table 4 for men, women, and women not using hormones. In this sample e 2 is associated with significantly lower total cholesterol, LDL-C, total apo B, and LDL apo B compared with those for e3. This is true for both men and women, although the magnitude of this difference is more pronounced in women. This difference is not explained by the presence of the e 21 e 2 genotype in men nor by any gender difference in frequency of the e 2 allele. Conversely, e 4 is associated with significantly higher total cholesterol, LDL-C, apo B, and LDL apo B in women only. When women taking oral contraceptive preparations or replacement hormones were excluded, the remaining women resembled the male sample with respect to e4 effects. This suggests that the use of hormonal preparations may influence apo E allele effects on LDL metabolism. No statistically significant influence of the e2 and e4 alleles on the HDL2-C or HDL3-C subfractions was observed.
In contrast to studies based on samples not selected for health, the average level of TGs in our sample was lower in those with the e2 allele and higher in those with the e 4 allele. However, permutation testing did not reveal any findings significant at the 0.05 level of probability with respect to TGs.
Between-gender comparisons are shown in Tables  5 and 6 . e2le2 men (n=4) were removed before these calculations because there were no corresponding e 21 e 2 women in the sample. Allele frequencies for men after excluding these individuals were as follows: e 2=0.055, e 3=0.819, and e 4=0.126. Differences (A) between men and women are given for the average level of each adjusted trait for those individuals who carry the e2 allele (A2), the e3 allele (A3), and the e 4 allele (A4). The null hypothesis of no gender effect was considered for each allele. For comparison, the gender difference, without considering the allelic classification (A total), is also presented. Men were significantly different from the total group of women (Table 5 ) in all contrasts, with the exception of the subset who carried the e 4 allele, for total cholesterol and LDL-C and the subset with the e2 allele for HDL3-C. Similarly, women not taking hormones and men (Table 6) were significantly different with respect to all measured traits, with the exception of e2 and e4 for HDL3-C and e2 for VLDL apo B. Table 7 summarizes the percentage of trait variability attributable to concomitant and genotypic influences as well as the percentage of sample variability for each trait that remained unexplained. We found that the combined influence of the concomitants was similar between genders, with the greatest contribution being evident for the LDL-related traits. These data suggest that the contribution of variation in concomitants is not influenced by hormone use.
However, the total contribution of genotypic variation in the apo E gene is consistently greater for women than for men. This difference was greatest for total cholesterol, LDL-C, and apo B. The unexplained fraction of variability for each trait is large, exceeding 61% in all cases. Between 61% and 86% of a, Percentage sum of squares attributable to regression of a trait on fourth-order polynomial of each concomitant: age, weight, height, BMI, glucose, and uric acid; b/a, total genotype contribution: percentage sum of squares attributable to apo E genotype differences given prior adjustment for concomitants (a); c, percentage sum of squares variables attributable to deviation of genotype means from the expected value based on average excesses of alleles; d, percentage sum of squares attributable to average excesses associated with the apo E alleles; chol, cholesterol; VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein; TG, triglyceride; apo, apolipoprotein; BMI, body mass index. */><0.001, the phenotypic variance in each of the three samples is explained by factors not considered here.
Discussion Apo E plays a central role in the regulation of lipid metabolism. The three common alleles of this polymorphic protein differ in amino acid sequence and are associated with different levels of many lipid and lipoprotein traits. The relative frequencies of the apo E alleles have been estimated for a number of populations representing a broad range of ethnic, cultural, and geographic differences (reviewed by Davignon et al 26 ) . Statistical evidence 26 supports the argument that the relative frequency of the e 3 allele is lower in Caucasian populations than in Japanese or Chinese populations, a finding that has been interpreted to indicate a possible role for the e 3 allele in determining the lower susceptibility to CHD in Oriental populations. The apparently higher frequency of the e 4 allele in Finland, where the risk of CHD is high compared with that of Japan, suggests that this allele may also contribute to differences in the prevalence of CHD. Table 8 presents data from representative populations ranked according to the relative frequency of the e3 allele. A wide range of frequencies for this allele has been reported. Its relative frequency is inversely related to that of the e 4 allele and to the relative risk of CHD.
Our sample has a relatively high frequency of e 3, thus resembling Japanese and octogenarian samples. 26 This comparison supports the hypothesis that the cardiovascular health of a population may be related to the proportion of individuals carrying the e3 allele. An increase in the frequency of the e3 allele is associated with correspondingly lower frequencies of both e2 and e4. It is known that the frequency of the e 2 allele is relatively increased in individuals with hyperlipidemia 12 ' 27 -29 and that this increased frequency is specifically associated with hypertriglyceridemia. It follows that in a sample selected for health, subjects bearing the e2 allele who might be at greater risk for hyperlipidemia and thus for cardiovascular disease are likely to have been excluded by the selection process, thus lowering its observed frequency in this study. Similarly, the relative frequency of the e 4 allele, which has been reported to be increased in hypercholesterolemic individuals, 28 -29 is decreased in our healthy subjects. Most studies have considered relative allele frequencies in pooled data from men and women. Comparison by Davignon et al 26 of data from the Framingham study 30 and the Munster 31 and Nancy 32 populations showed no statistically significant differences in allele frequencies between genders. Similarly, Cumming and Robertson 33 cited a lack of evidence for gender differences in allele frequencies as the rationale for performing analyses with pooled data. Our study further supports the absence of gender-specific differences in allele frequency. However, as shown in Table 3 and discussed below, the contribution of a particular allele to variability in trait levels is different in men and women.
Our estimates of average excess are consistent with previous studies showing the association of lower total cholesterol, LDL-C, LDL apo B, and total apo B in those individuals with the e 2 allele. 26 Selection for health and the separate consideration of men and women suggest that the impact of the gene may be influenced by factors that remain undefined. Specifically, we found that the average excesses of the alleles were not of the same magnitude in the two genders, the e 4 association being statistically significant in women only despite the absence of significant gender difference in allele frequency.
In contrast to inferences drawn from studies of populations not selected for health, 26 we found that the presence of e2 tended to be associated with lower TG levels and e 4 with higher TG levels in our subjects. Although these differences do not reach statistical significance (with the exception of VLDL-C in men), the fact that the observed trend is contrary to that previously reported is of particular interest. To investigate the possibility that our adjustments for glucose and uric acid levels were responsible for these findings, all analyses were repeated after ignoring these adjustments. Our conclusions were not altered. We therefore postulate that the presence of confounding factors (such as obesity, diabetes, etc.) in other samples may partially explain previous observations of a greater relative increase in TGs in individuals bearing the e2 allele. Our exclusion of individuals with any of these confounders could thus explain the lack of such an association.
Between-gender comparisons (Tables 5 and 6 ) confirm our previous results regarding differences in allele effects. Comparison of all women («=201) with men with respect to cholesterol and LDL-C reveals a significant difference for those subgroups representing the e2 and e3 alleles but no significant differences within the subgroups representing the e4 allele. This result suggests the presence of a gene by gender interaction for only two of the 11 traits considered. Furthermore, women not taking hormones (n = 143) were significantly different from men for each of the dependent variables for all three alleles, except in the case of HDL3-C, for which men were not significantly different from these women. We conclude that gender and hormone effects on levels of most traits that are measures of lipid metabolism are independent of common allelic variation of the apo E gene.
Our analysis of sample variability suggests that a major fraction is attributable to measured concomitant variables. Furthermore, the percentage of trait variability attributable to these concomitants is similar between genders, with the contribution being greatest for LDL-related traits and least for HDL-C. This probably reflects a greater influence of external environments on LDL metabolism, which is measured by concomitants, than on HDL metabolism, which is driven more by variability in the internal environment. In contrast, there is a marked gender difference in the proportion of variability attributable to apo E variation, as expected from the gender comparisons of allele effects. The variance of LDL-C, total cholesterol, and apo B associated with the apo E polymorphism is higher in women. These genderspecific genotypic effects suggest the presence of factors that influence LDL metabolism in healthy women only.
Reduction in the genetic variance of traits that are measures of LDL metabolism by exclusion of women who take exogenous hormones suggests that hormone therapy may have a role in determining apo E allele effects. This may appear to be at odds with the findings of Eichner et al, 35 who did not find an effect of apo E phenotype on changes in lipids, lipoproteins, or apolipoproteins with aging and menopause. A meaningful comparison of the two studies, however, is not possible because of differences in the nature of the samples studied. Exclusion of healthy women taking exogenous hormones creates a subgroup of women who more closely resemble a sample of healthy men. Indeed, we can infer that women bearing the e 4 allele and taking hormones have an associated increase in blood cholesterol, which is different from their counterparts who are not taking hormones, suggesting that the genotype by environment interaction is different in these two groups. It is noteworthy that this contribution of hormones to the influence of the e 4 allele appears to relate only to cholesterol metabolism. In addition, hormone use does not influence the contribution of concomitant variables to phenotypic variability of these traits.
It is apparent that a major fraction of phenotypic variance for each trait remains unexplained. This supports the argument that intermediate traits that link genetic variation to risk of CHD are influenced by variation in many factors, most of which are yet to be defined.
In conclusion, our study of the influence of the common apo E alleles in individuals selected for health has provided the following insights: 1) The frequency of the e 3 allele is increased. 2) In contrast to the population at large, lower TG levels are associated with individuals bearing the e 2 allele. 3) Apo E allele effects are different between genders, the influence of the e 4 allele being greater in women. 4) The fraction of trait variability attributable to concomitant variables is similar between genders and is greatest for LDL-C-related traits. 5) The influence of apo E genotypic variation is much less than the contribution of concomitants. Nonetheless, genotypic effects account for a greater percentage of interindividual variability in women. This difference is greatest for total cholesterol, LDL-C, and total apo B and appears attributable, at least in part, to differences in environment, specifically hormonal milieu. This would suggest that exogenous factors such as the use of hormone therapy in women, be it postmenopausal replacement or oral contraceptive use, influences the effects of apo E alleles on measures of LDL metabolism. This possibility should be further addressed within the context of a specific study that would consider the various types and combinations of hormonal preparations. Nonetheless, the importance of considering genotype by environment interaction effects in a model to explain phenotypic variance is emphasized. 6) Finally, the fraction of phenotypic variance that remains unexplained after considering variation in concomitant traits and the apo E polymorphism remains large for both men and women.
This study confirms that major risk factors for CHD have a truly multifactorial etiology. The existence of gender differences in allele effects introduces a new order of complexity and indicates that data pooling or adjustment for gender effects is an oversimplification that should be avoided. adaptations to permutation testing used in this manuscript. 
